Skip to main content

Table 1 Subgroup analysis of the any grade adverse events

From: The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis

Experimental vs. control No. of studies RR 95% CI p Heterogeneity
(I2) (%)
Any grade adverse events 8 1.04 0.99–1.10 0.16 97
Any grade abdominal pain 9 0.97 0.84–1.12 0.68 36
Any grade anemia 9 3.40 1.86–6.19 < 0.001 95
Any grade arthralgia 7 0.94 0.82–1.07 0.32 0
Any grade constipation 9 1.16 0.91–1.49 0.22 75
Any grade decreased appetite 6 1.45 1.21–1.74 < 0.001 7
Any grade diarrhea 8 1.23 1.07–1.40 0.003 20
Any grade dizziness 6 1.46 1.11–1.94 0.008 36
Any grade fatigue 9 1.36 1.20–1.53 < 0.001 65
Any grade headache 8 1.35 1.04–1.74 0.02 68
Any grade nausea 9 1.71 1.35–2.17 < 0.001 92
Any grade neutropenia 8 1.88 1.23–2.87 0.003 89
Any grade thrombocytopenia 7 3.59 1.65–7.78 0.001 91
Any grade vomiting 9 1.82 1.48–2.23 < 0.001 60